Insulin icodec

Published

dm+d

Unassigned

New Medicines

Type 2 diabetes mellitus

Information

New molecular entity
Novo Nordisk
Novo Nordisk

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A long-acting basal insulin analogue, intended for once-weekly treatment [1].
Currently 3.8 million people in the UK are diagnosed with diabetes (90% type 2), and it is estimated that a further 1 million people with type 2 diabetes have not yet been diagnosed.
Type 2 diabetes mellitus
Subcutaneous injection